arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

aTYR PHARMA INC

ATYR
$0.52 ▲ +0.02 (+4.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

aTYR PHARMA INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $48.4M
Dividend Yield
Revenue Growth -19.1%
Op. Margin None
ROIC -115.0%
FCF / Share $-0.67
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$190.00K
↓ -19.1%
Net Income Profit after all expenses
$-74.12M
↓ -15.8%
Operating Margin Operating profit as % of sales
-446.8%
↓ -193.6%
FCF / Share Free cash flow per share
$-0.67
↑ +28.4%
Long-Term Debt Long-term obligations
$8.26M
↓ -43.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
8
Financial Health
5
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters